Ost-müük Benitec Biopharma Inc. - BNTC CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.0243 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 0.2231 |
Avatud* | 0.2197 |
Aastane muutus* | -80.21% |
Päeva ulatus* | 0.2014 - 0.2197 |
52 nädala ulatus | 0.13-2.10 |
Keskmine maht (10 päeva) | 481.94K |
Keskmine maht (3 kuud) | 7.11M |
Turukapitalisatsioon | 6.34M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 27.98M |
Tulu | 68.00K |
EPS | -1.44 |
Dividendid (% kasumist) | N/A |
Beeta | 1.15 |
Järgmine tuluaruande kuupäev | Aug 31, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 0.2135 | -0.0061 | -2.78% | 0.2196 | 0.2207 | 0.2014 |
May 25, 2023 | 0.2231 | 0.0283 | 14.53% | 0.1948 | 0.2971 | 0.1896 |
May 24, 2023 | 0.1929 | -0.0077 | -3.84% | 0.2006 | 0.2007 | 0.1821 |
May 23, 2023 | 0.1969 | 0.0041 | 2.13% | 0.1928 | 0.2014 | 0.1916 |
May 22, 2023 | 0.1918 | 0.0001 | 0.05% | 0.1917 | 0.2063 | 0.1820 |
May 19, 2023 | 0.1972 | 0.0056 | 2.92% | 0.1916 | 0.2016 | 0.1914 |
May 18, 2023 | 0.1889 | 0.0069 | 3.79% | 0.1820 | 0.1985 | 0.1797 |
May 17, 2023 | 0.1871 | -0.0144 | -7.15% | 0.2015 | 0.2085 | 0.1822 |
May 16, 2023 | 0.2063 | 0.0094 | 4.77% | 0.1969 | 0.2094 | 0.1962 |
May 15, 2023 | 0.2030 | 0.0017 | 0.84% | 0.2013 | 0.2153 | 0.2013 |
May 12, 2023 | 0.2033 | -0.0066 | -3.14% | 0.2099 | 0.2112 | 0.2010 |
May 11, 2023 | 0.2178 | -0.0017 | -0.77% | 0.2195 | 0.2255 | 0.2011 |
May 10, 2023 | 0.2183 | 0.0086 | 4.10% | 0.2097 | 0.2208 | 0.2012 |
May 9, 2023 | 0.2140 | 0.0123 | 6.10% | 0.2017 | 0.2198 | 0.2013 |
May 8, 2023 | 0.2158 | 0.0083 | 4.00% | 0.2075 | 0.2169 | 0.2010 |
May 5, 2023 | 0.2078 | 0.0067 | 3.33% | 0.2011 | 0.2329 | 0.1930 |
May 4, 2023 | 0.2127 | 0.0116 | 5.77% | 0.2011 | 0.2388 | 0.2010 |
May 3, 2023 | 0.2052 | 0.0066 | 3.32% | 0.1986 | 0.2111 | 0.1983 |
May 2, 2023 | 0.1895 | -0.0023 | -1.20% | 0.1918 | 0.1920 | 0.1829 |
May 1, 2023 | 0.1919 | 0.0052 | 2.79% | 0.1867 | 0.1951 | 0.1834 |
Benitec Biopharma Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Thursday, August 31, 2023 | ||
Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q4 2023 Benitec Biopharma Inc Earnings Release Q4 2023 Benitec Biopharma Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 8, 2023 | ||
Kellaaeg (UTC) (UTC) 13:30 | Riik US
| Sündmus Q1 2024 Benitec Biopharma Inc Earnings Release Q1 2024 Benitec Biopharma Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0.073 | 0.059 | 0.102 | 11.0403 | 3.0723 |
Tulu | 0.073 | 0.059 | 0.102 | 11.0403 | 3.0723 |
Kulud, Kokku | 0.009 | 0.123 | -0.185 | 0.404985 | 0.299915 |
Brutokasum | 0.064 | -0.064 | 0.287 | 10.6353 | 2.77238 |
Kogu tegevuskulu | 17.927 | 13.655 | 8.383 | 8.93893 | 10.8136 |
Müük/Üldine/admin kulud, kokku | 6.646 | 6.512 | 5.567 | 6.32282 | 5.80279 |
Uuringud ja arendus | 11.272 | 7.02 | 3.001 | 2.06416 | 4.58185 |
Ootamatud kulutused (tulu) | |||||
Tulud majandustegevusest | -17.854 | -13.596 | -8.281 | 2.1014 | -7.74126 |
Intressitulud (kulu), muud tulud, neto | -0.275 | -0.323 | -0.027 | 0.627095 | 0.00133 |
Netotulu enne makse | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Netotulu pärast makse | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Netotulu enne erikulusid | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Netotulu | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Arvestatav tulu, v a erikulud | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Arvestatav tulu, koos erikuludega | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Jaotamisele kuuluv netotulu | -18.208 | -13.882 | -8.274 | 2.72251 | -7.7406 |
Keskmine jaotamisele kuuluv aktsia kohta | 8.17169 | 4.29542 | 1.02119 | 171.353 | 140.303 |
Jaotatav EPS, v a erakorralised kulud | -2.22818 | -3.23182 | -8.10229 | 0.015887 | -0.055168 |
Dividends per Share - Common Stock Primary Issue | |||||
Jaotamisele kuuluv normaal-EPS | -2.22818 | -3.23182 | -8.10229 | 0.01592 | -0.055168 |
Depreciation / Amortization | 0.146965 | 0.12901 | |||
Gain (Loss) on Sale of Assets | -0.005985 | -0.000665 | |||
Muud, neto | -0.079 | 0.037 | 0.034 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0.054 | 0.014 | 0 | 0 | 0.048 |
Tulu | 0.054 | 0.014 | 0 | 0 | 0.048 |
Kulud, Kokku | 0.009 | 0 | |||
Brutokasum | -0.009 | 0.048 | |||
Kogu tegevuskulu | 4.395 | 5.624 | 4.58 | 4.738 | 3.508 |
Müük/Üldine/admin kulud, kokku | 1.228 | 1.863 | 1.92 | 1.553 | 1.337 |
Uuringud ja arendus | 3.167 | 3.761 | 2.66 | 3.176 | 2.171 |
Tulud majandustegevusest | -4.341 | -5.61 | -4.58 | -4.738 | -3.46 |
Intressitulud (kulu), muud tulud, neto | -0.056 | 0.149 | -0.513 | -0.279 | 0.214 |
Muud, neto | 0 | 0.05 | -0.05 | -0.029 | |
Netotulu enne makse | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Netotulu pärast makse | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Netotulu enne erikulusid | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Netotulu | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Arvestatav tulu, v a erikulud | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Arvestatav tulu, koos erikuludega | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Jaotamisele kuuluv netotulu | -4.397 | -5.411 | -5.093 | -5.067 | -3.275 |
Keskmine jaotamisele kuuluv aktsia kohta | 27.9812 | 27.5618 | 10.8557 | 8.17169 | 8.17169 |
Jaotatav EPS, v a erakorralised kulud | -0.15714 | -0.19632 | -0.46915 | -0.62007 | -0.40077 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.15714 | -0.19632 | -0.46915 | -0.62007 | -0.40077 |
Other Operating Expenses, Total |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 4.82 | 20.608 | 10.809 | 17.7841 | 13.8952 |
Raha ja lühiajalised investeeringud | 4.062 | 19.769 | 9.801 | 15.0237 | 10.783 |
Raha ja ekvivalendid | 4.062 | 0 | 4.57 | 14.9033 | 10.6965 |
Laekumata arved, neto | 0.003 | 0.025 | 0.059 | 2.40464 | 2.82957 |
Accounts Receivable - Trade, Net | 0.003 | 0.025 | 0.059 | 2.40464 | 2.82957 |
Other Current Assets, Total | 0.019 | 0.032 | 0.088 | 0.282625 | |
Total Assets | 5.973 | 21.379 | 11.587 | 18.2383 | 14.1904 |
Property/Plant/Equipment, Total - Net | 0.993 | 0.577 | 0.769 | 0.44555 | 0.212135 |
Total Current Liabilities | 2.532 | 1.369 | 1.136 | 2.50439 | 1.69375 |
Accounts Payable | 0.422 | 0.274 | 0.282 | 1.39716 | 1.58004 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.071 | 0.174 | 0.25 | 0.974225 | 0.113715 |
Total Liabilities | 3.091 | 1.369 | 1.349 | 2.50439 | 1.72567 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.559 | 0 | 0.213 | 0 | 0.03192 |
Total Equity | 2.882 | 20.01 | 10.238 | 15.7339 | 12.4648 |
Common Stock | 0.001 | 0.001 | 0.001 | 109.118 | 109.118 |
Retained Earnings (Accumulated Deficit) | -148.327 | -130.119 | -116.636 | -92.4097 | -96.6531 |
Total Liabilities & Shareholders’ Equity | 5.973 | 21.379 | 11.587 | 18.2383 | 14.1904 |
Total Common Shares Outstanding | 8.17169 | 8.17169 | 1.10837 | 257.029 | 257.029 |
Lühiajalised investeeringud | 0.120365 | 0.08645 | |||
Long Term Investments | 0.008645 | 0.083125 | |||
Prepaid Expenses | 0.736 | 0.782 | 0.861 | 0.355775 | |
Property/Plant/Equipment, Total - Gross | 2.175 | 1.595 | 1.565 | 1.08063 | |
Accumulated Depreciation, Total | -1.182 | -1.018 | -0.796 | -0.635075 | |
Accrued Expenses | 2.039 | 0.921 | 0.604 | 0.133 | |
Other Equity, Total | -1.245 | -1.455 | -1.953 | -0.974225 | |
Cash | 19.769 | 5.231 | |||
Other Long Term Assets, Total | 0.16 | 0.194 | 0.009 | ||
Additional Paid-In Capital | 152.453 | 151.583 | 128.826 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 7.395 | 10.975 | 17.081 | 4.82 | 8.841 |
Raha ja lühiajalised investeeringud | 6.551 | 10.537 | 16.534 | 4.062 | 8.63 |
Cash | 8.63 | ||||
Raha ja ekvivalendid | 6.551 | 10.537 | 16.534 | 4.062 | |
Laekumata arved, neto | 0.056 | 0.068 | 0.003 | 0.003 | 0.005 |
Accounts Receivable - Trade, Net | 0.056 | 0.068 | 0.003 | 0.003 | 0.005 |
Prepaid Expenses | 0.774 | 0.356 | 0.531 | 0.736 | 0.206 |
Total Assets | 8.22 | 11.905 | 18.115 | 5.973 | 10.064 |
Property/Plant/Equipment, Total - Net | 0.695 | 0.789 | 0.89 | 0.993 | 1.042 |
Property/Plant/Equipment, Total - Gross | 1.992 | 2.054 | 2.114 | 2.175 | 2.221 |
Accumulated Depreciation, Total | -1.297 | -1.265 | -1.224 | -1.182 | -1.179 |
Other Long Term Assets, Total | 0.13 | 0.141 | 0.144 | 0.16 | 0.181 |
Total Current Liabilities | 3.153 | 2.489 | 3.011 | 2.532 | 1.909 |
Accounts Payable | 0.635 | 0.531 | 0.608 | 0.422 | 0.1 |
Accrued Expenses | 2.482 | 1.917 | 2.275 | 2.039 | 1.753 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.036 | 0.041 | 0.128 | 0.071 | 0.056 |
Total Liabilities | 3.507 | 2.911 | 3.502 | 3.091 | 2.544 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.354 | 0.422 | 0.491 | 0.559 | 0.635 |
Total Equity | 4.713 | 8.994 | 14.613 | 2.882 | 7.52 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.001 | 0.001 |
Additional Paid-In Capital | 168.791 | 168.72 | 168.768 | 152.453 | 152.285 |
Retained Earnings (Accumulated Deficit) | -163.228 | -158.831 | -153.42 | -148.327 | -143.26 |
Other Equity, Total | -0.853 | -0.898 | -0.738 | -1.245 | -1.506 |
Total Liabilities & Shareholders’ Equity | 8.22 | 11.905 | 18.115 | 5.973 | 10.064 |
Total Common Shares Outstanding | 27.9812 | 27.9812 | 25.8095 | 8.17169 | 8.17169 |
Other Current Assets, Total | 0.014 | 0.014 | 0.013 | 0.019 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Raha majandustegevusest | -15.899 | -12.832 | -7.535 | 3.8949 | -6.51301 |
Cash Receipts | 11.7466 | 0.23009 | |||
Cash Payments | -10.7012 | -9.64117 | |||
Muutused tööjõus | -15.899 | -12.832 | -7.535 | 2.84952 | 2.89807 |
Tulu investeeringutelt | -0.013 | -0.221 | -0.094 | -0.37905 | -0.097755 |
Kapitalikulutused | -0.013 | -0.221 | -0.095 | -0.38304 | -0.055195 |
Rahavood investeeringutelt | 0 | 22.522 | 1.77 | 0 | 5.65715 |
Rahavoogudesse investeerimine | 0 | -3.228 | -0.48 | 0 | -0.208145 |
Aktsiate emiteerimine (tagasiost), neto | 0 | 25.75 | 2.25 | 0 | 5.8653 |
Muutused valuutakursside kõikumisest | 0.204 | 0.499 | -0.058 | 0.690935 | 0.09576 |
Rahaline kogumuutus | -15.708 | 9.968 | -5.917 | 4.20679 | -0.85785 |
Muud rahavood investeeringutelt, kokku | 0 | 0.001 | 0.00399 | -0.04256 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Cash From Operating Activities | -13.917 | -9.888 | -4.045 | -15.899 | -11.044 |
Changes in Working Capital | -13.917 | -9.888 | -4.045 | -15.899 | -11.044 |
Cash From Investing Activities | 0 | 0 | -0.013 | 0 | |
Capital Expenditures | -0.013 | 0 | |||
Other Investing Cash Flow Items, Total | 0 | 0 | |||
Cash From Financing Activities | 16.015 | 16.015 | 16.015 | 0 | 0 |
Financing Cash Flow Items | -1.869 | -1.869 | -1.869 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 17.884 | 17.884 | 17.884 | 0 | 0 |
Foreign Exchange Effects | 0.391 | 0.348 | 0.501 | 0.204 | -0.095 |
Net Change in Cash | 2.489 | 6.475 | 12.471 | -15.708 | -11.139 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 35.7383 | 10000000 | 0 | 2023-03-31 | LOW |
Oliveira (Steven Michael) | Individual Investor | 3.8746 | 1084171 | 1084171 | 2022-09-16 | |
Nemean Asset Management, LLC | Corporation | 3.5738 | 1000000 | 0 | 2022-09-16 | |
Empery Asset Management, L.P. | Investment Advisor/Hedge Fund | 2.8478 | 796837 | 796837 | 2022-09-30 | LOW |
Suvretta Capital Management, LLC | Hedge Fund | 2.7483 | 769000 | 0 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.8037 | 224879 | -150652 | 2023-03-31 | HIGH |
Walleye Capital LLC | Hedge Fund | 0.7719 | 215989 | -128026 | 2023-03-31 | LOW |
Alpha Capital Aktiengesellschaft | Holding Company | 0.4455 | 124662 | -131605 | 2021-12-31 | LOW |
Virtu Americas LLC | Research Firm | 0.4343 | 121514 | 40647 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.2672 | 74773 | 0 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1723 | 48223 | -1246 | 2023-03-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.1626 | 45500 | -288129 | 2023-03-31 | MED |
Two Sigma Investments, LP | Hedge Fund | 0.0956 | 26747 | -80484 | 2023-03-31 | HIGH |
Cantor Fitzgerald, L.P | Investment Advisor | 0.0895 | 25050 | 0 | 2023-03-31 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0766 | 21438 | 0 | 2023-03-31 | LOW |
Private Advisor Group LLC | Investment Advisor | 0.047 | 13157 | 13157 | 2023-03-31 | LOW |
Axiom Asset Management | Investment Advisor | 0.0463 | 12950 | 0 | 2023-03-31 | LOW |
Cetera Advisor Networks LLC | Investment Advisor | 0.0441 | 12351 | -4282 | 2023-03-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0422 | 11813 | 0 | 2023-03-31 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.027 | 7561 | 0 | 2023-03-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Benitec Biopharma Inc. Company profile
Ettevõttest Benitec Biopharma Inc.
Benitec Biopharma Inc on Austraalias asuv biotehnoloogia ettevõte. Ettevõte keskendub terapeutilise tehnoloogiaplatvormi arendamisele, mis ühendab ribonukleiinhappe (RNA) sekkumise geeniteraapiaga eesmärgiga vaigistada haigust põhjustavad geenid üheainsa manustamisega. Ettevõtte tehnoloogiat, desoksüribonukleiinhappe (DNA) suunatud RNA-interferentsi (ddRNAi), kasutatakse tootekandidaatide väljatöötamiseks krooniliste ja eluohtlike inimhaiguste, sealhulgas harvaesinevate haiguste ja nakkushaiguste valdkonnas. Ettevõtte tooteprogrammi kuuluvad BB-301 ja BB-103. Ettevõtte juhtiv tootekandidaat BB-301 on ette nähtud okulofarüngeaalse lihasdüstroofia (OPMD) raviks. BB-103 on väljatöötamisel kroonilise B-hepatiidi viiruse infektsiooni raviks.
Industry: | Biotechnology & Medical Research (NEC) |
3940 Trust Way
94545
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com